| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRTAM |
| Uniprot No | O95727 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-286aa |
| 氨基酸序列 | SLTNHTETIT VEEGQTLTLK CVTSLRKNSS LQWLTPSGFT IFLNEYPALK NSKYQLLHHS ANQLSITVPN VTLQDEGVYK CLHYSDSVST KEVKVIVLAT PFKPILEASV IRKQNGEEHV VLMCSTMRSK PPPQITWLLG NSMEVSGGTL HEFETDGKKC NTTSTLIIHT YGKNSTVDCI IRHRGLQGRK LVAPFRFEDL VTDEETASDA LERNSLSSQD PQQPTSTVSV TEDSSTSEID KEEKEQTTQD PDLTTEANPQ YLGLARKKS |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CRTAM重组蛋白的参考文献概览：
1. **"Structural basis for the interaction between the cytotoxic T lymphocyte glycoprotein CRTAM and its ligand necl-2"**
- **作者**: Santiago, C., et al.
- **摘要**: 解析了CRTAM重组蛋白及其配体necl-2的晶体结构，揭示了二者结合的分子机制，为T细胞和NK细胞免疫调控提供结构基础。
2. **"CRTAM regulates ligand-specific activation of CD4+ T cells"**
- **作者**: Ishida, H., et al.
- **摘要**: 利用重组CRTAM蛋白研究其与CD155的相互作用，证明CRTAM通过调节T细胞受体信号通路影响Th1细胞分化及功能。
3. **"Recombinant CRTAM enhances NK cell-mediated cytotoxicity in vitro"**
- **作者**: Verdino, P., et al.
- **摘要**: 通过重组CRTAM蛋白实验，证实其能促进NK细胞与靶细胞结合并增强细胞毒性，提示其在抗肿瘤免疫中的潜在应用。
4. **"CRTAM modulates intestinal mucosal immunity through epithelial cell interactions"**
- **作者**: Zheng, Y., et al.
- **摘要**: 使用重组CRTAM蛋白研究肠道上皮细胞与免疫细胞的互作，发现其通过调控IL-22分泌参与黏膜屏障修复及炎症反应。
这些文献覆盖了CRTAM重组蛋白在结构解析、免疫调控及疾病模型中的研究。
CRTAM (Cytotoxic and Regulatory T-cell Molecule) is a cell surface protein belonging to the immunoglobulin superfamily, primarily expressed on activated cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and mucosal-associated invariant T (MAIT) cells. It functions as a receptor involved in cell-cell interactions, particularly in immune responses. Structurally, CRTAM contains an extracellular immunoglobulin domain, a transmembrane region, and a cytoplasmic tail with signaling motifs. Its ligand, Necl-2 (nectin-like molecule 2. also known as CADM1), is expressed on epithelial cells, dendritic cells, and neurons, facilitating adhesion and signaling between immune cells and target tissues.
The CRTAM/Necl-2 interaction plays a role in modulating immune activation, tissue homeostasis, and inflammatory processes. In T cells, CRTAM engagement promotes cytotoxicity, cytokine secretion (e.g., IFN-γ), and survival signals, enhancing anti-pathogen or antitumor responses. Conversely, it may also regulate immune tolerance by influencing regulatory T-cell (Treg) function. Dysregulation of CRTAM has been implicated in autoimmune diseases, chronic inflammation, and cancer progression, highlighting its dual role in immune regulation.
Recombinant CRTAM protein, produced via mammalian or bacterial expression systems, is a valuable tool for studying these mechanisms. It enables in vitro and in vivo exploration of CRTAM-ligand binding, downstream signaling pathways, and therapeutic potential. Researchers use it to develop blocking antibodies, assess immunomodulatory therapies, or engineer CRTAM-based biologics for conditions like cancer, infectious diseases, or autoimmune disorders. Recent studies also suggest its involvement in neuroimmune interactions, expanding its relevance to neurological diseases. Despite progress, further research is needed to fully elucidate its context-dependent functions and translational applications.
×
